Purdue Pharma L.P., et al. v. Amanda Morales

District Court, S.D. New York·Decided February 20, 2026·No. 7:25-cv-10158·Unknown

Opinion

ihe Court directs Appellee Furdue Pharma LF. to respond to Appellant's DOCUMENT motion by March 6, 2026. Appellee need not submit a fully briefed WCECTRGKIGATLY FILED response. The Clerk of Court is respectfully directed to terminate the Doc #: motion at ECF No. 40 and to mail this Endorsement to the pro se DATE FILED: 2/20/2026 Appellant at the address listed on ECF. co ORDERED: Dated: February 20, 2026. _ CLer —, White Plains, NY United States District Judge UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK

Purdue Pharma L.P.,st al. Chapter 11 PURDUE PHARMA L.P., P.F. LABORATORIES, INC., PURDUE PHARMACEUTICALS L.P., Case No. 7:25-ev- 10158

PURDUE PHARMA TECHNOLOGIES, INC., and RHODES TECHNOLOGIES, Appellee

AMANDA MORALES Appellant

. . Appellant’s Motion for Stay Pending Appeal

In the absence of a stay, the plaintiff will face the dilemma of either taking action on the underlying administrative complaint — which would in all likelihood moot its appeal — or permanently losing exclusive civil enforcement jurisdiction over the case by triggering a private right of action under 52 U.S.C. § 30109(a)(8)(C). Conversely, defendants will face only minimal harm if a stay of the PLANTIFF is conformance period is granted, as the additional time necessary for appellate review will only marginally add to the total duration of this case, which involves due process violations and wrongful death claims that have merit.

Non-Core Claim Failure to warn serotonin syndrome is not a bankruptcy issue and should be transferred to district court. My father died in 2010 and Purdue Pharma failed to warn about OxyContin interactions with antidepressants citalopram and amitriptyline that can cause serotonin syndrome and can be fatal. Purdue changed the warning label in 2016. I found out about the label change in 2021 and have been denied due process for my non-core claim. This timeline supports foreseeability and knowledge, not a bankruptcy created issue. Nothing about the claim depends on the bankruptcy estate. The bankrupcy courts Modified Bench Ruling states “Objections Related to Classification of Claims Other objections relate to classification of claims under the Plan. Certain pro se objectors oppose the Plan’s classification scheme, arguing that their claims are fundamentally different from others based on the nature of the injury or the damages sought. See, e.g., Morales Obj. [ECF. No. 7355 at 8-11];But these distinctions do not meaningfully alter the priority or legal bases of these claims. Moreover, any attempt to divide the creditor body in the granular way suggested by objectors would result in an unworkably complex classification scheme. “distinctions do not meaningfully alter the priority or legal bases of these claims” — is not just wrong, it’s legally incoherent in the context of , state-law wrongful-death claims like mine.

ARGUMENT Priority and legal basis defined by distinctions the court ignored My claim is: • a state-law wrongful-death tort, • arising from failure to warn, • involving post-petition conduct (2016 label change confirming the risk), • and non-core under 28 U.S.C. § 157(b). Those distinctions : • the legal basis (state tort law, not bankruptcy law), • the priority (personal injury tort claims have unique treatment under § 1123(a)(4) and § 1129(a)(7)), • and the forum (Article III court with a jury right). To say these distinctions “do not meaningfully alter” anything is to pretend the Bankruptcy Code doesn’t exist Non-core tort claims cannot be lumped together without violating Article III The Supreme Court has been explicit: Bankruptcy courts cannot finally adjudicate non-core tort claims without consent ( , , ). Your claim: • is non-core, • carries a jury-trial right, • and cannot be re-characterized as a “bankruptcy claim” simply because Purdue filed Chapter 11. When the court says distinctions don’t matter, it is effectively saying: “We can treat non-core tort claims as if they were core bankruptcy claims.” That is unconstitutional Wrongful-death claims have unique damages structures that alter priority Wrongful-death damages include: • loss of life, • loss of consortium, • loss of support, • medical expenses, • funeral expenses, • punitive damages (in many states). These are not the same as: • OUD claims, • NAS claims, • medical monitoring claims, • third-party payor claims. Different damages → different valuation → different classification → different priority. To say distinctions don’t matter is to erase the entire structure of tort law. The court’s statement contradicts § 1123(a)(4) Section 1123(a)(4) requires: “the same treatment for each claim or interest of a particular class.”

Free access — add to your briefcase to read the full text and ask questions with AI

Purdue Pharma L.P., et al. v. Amanda Morales, (S.D.N.Y. 2026).

Purdue Pharma L.P., et al. v. Amanda Morales (Purdue Pharma L.P., et al. v. Amanda Morales) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Anderson v. Liberty Lobby, Inc.
477 U.S. 242 (Supreme Court, 1986)
Granfinanciera, S.A. v. Nordberg
492 U.S. 33 (Supreme Court, 1989)
Nken v. Holder
556 U.S. 418 (Supreme Court, 2009)
In Re Pasquariello
16 F.3d 525 (Third Circuit, 1994)
Terhune v. A. H. Robins Co.
577 P.2d 975 (Washington Supreme Court, 1978)
Little v. PPG Industries, Inc.
579 P.2d 940 (Court of Appeals of Washington, 1978)
In Re Gray
447 B.R. 524 (E.D. Michigan, 2011)
In Re Fairfield Sentry Ltd. Litigation
458 B.R. 665 (S.D. New York, 2011)
Cigar Ass'n of Am. v. U.S. Food & Drug Admin.
317 F. Supp. 3d 555 (D.C. Circuit, 2018)
Nat'l Ass'n for the Advancement of Colored People v. Trump
321 F. Supp. 3d 143 (D.C. Circuit, 2018)